CYTAMED

Project "CYTAMED" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

The aim of the current project is to develop a strong business plan that includes market analysis and clinical validation strategies to commercialise CytaCoat. 1 in 18 patients in a European hospital acquire Healthcare-Associated Infections (HAIs) mainly as a result of colonisation and formation of microbial biofilms on the surface of medical devices that are in lengthy contact with patients. At present, antimicrobial substances and silver agent coating are used as preventative measures, while antibiotics are used for treatment following HAIs. These strategies either contribute to antimicrobial resistance or potentially dangerous due to the release of harmful silver substances in the body. To overcome this, CytaCoat has developed a unique and stable antimicrobial coating that uses non-toxic, biocompatible organic compounds that strongly bind to the surface of the device through covalent bonding. This impedes microbial colonization and reduces the likelihood of antimicrobial resistance to the coating. These features distinguish CytaCoat from all competing products on the market. The first application for the coating are neonatal nasal prongs for non-invasive ventilation support, however the coating can be applied to all invasive and non-invasive medical devices. The research performed to date strongly supports CytaCoat’s ability to hinder microbial colonisation. The coating is easily applied to all devices using a defined protocol developed by the company. This project will help facilitate the road towards commercialisation.